FrancophonIA/ELRC3.0 huggingface dataset:
English: The most commonly reported undesirable effects related to pemetrexed, whether used as monotherapy or in combination, are bone marrow suppression manifested as anaemia, neutropenia, leukopenia, thrombocytopenia; and gastrointestinal toxicities, manifested as anorexia, nausea, vomiting, diarrhoea, constipation, pharyngitis, mucositis, and stomatitis.
Danish: De hyppigst indberettede bivirkninger relateret til pemetrexed ved både monoterapi og kombinationsbehandling, er knoglemarvssuppression med anæmi, neutropeni, leukopeni, trombocytopeni, samt gastrointestinal toksicitet med anoreksi, kvalme, opkastning, diaré, forstoppelse, pharyngitis, mucositis og stomatitis.
English: Pemetrexed at a dose of 500 mg/m was studied as a single-agent in 64 chemonaive patients with malignant pleural mesothelioma.
Danish: Pemetrexed i en dosis på 500 mg/m blev undersøgt som monoterapi til 64 patienter med malignt pleuramesoteliom, som ikke tidligere havde modtaget kemoterapi.
English: Contact your doctor if you get a severe rash, or itching, or blistering (Stevens-Johnson
Danish: Fortæl det til din læge, hvis du får alvorligt udslæt, kløe eller blæredannelse (Stevens-Johnsons syndrom eller toksisk epidermal nekrolyse).
English: The appropriate volume of reconstituted pemetrexed solution must be further diluted to 100 ml with 5% glucose intravenous infusion and administered as an intravenous infusion over 10 minutes.
Danish: Den passende mængde rekonstituerede pemetrexedopløsning skal fortyndes yderligere til 100 ml med 5 % glucose infusionsvæske og indgives som langsom intravenøs infusion over 10 minutter.
English: Pemetrexed Fresenius Kabi in combination with cisplatin The recommended dose of Pemetrexed Fresenius Kabi is 500 mg/m of body surface area (BSA) administered as an intravenous infusion over 10 minutes on the first day of each 21-day cycle.
Danish: Pemetrexed Fresenius Kabi i kombination med cisplatin Den anbefalede dosis af Pemetrexed Fresenius Kabi er 500 mg/m legemsoverflade indgivet som intravenøs infusion over 10 minutter på den første dag i hver 21-dages-serie.
English: The percentage of patients that received post study treatment was 64.3% for pemetrexed and 71.7% for placebo.
Danish: 64,3 % af pemetrexedpatienterne og 71,7 % af placebo-patienterne fik behandling efter studiet.
English: Radiation recall (a skin rash like severe sunburn) which can occur on skin that has previously been exposed to radiotherapy, from days to years after the radiation.
Danish: Sjældne (kan påvirke op til 1 ud af 1.000 patienter) Radiation recall (et hududslæt, der ligner en alvorlig solskoldning), som kan opstå på hud, der tidligere har været udsat for strålebehandling, dage eller op til år efter strålebehandlingen.
English: Type I, clear, colourless glass vial, with 20 mm chlorobutyl rubber stopper and sealed with green flip-off aluminium seal.
Danish: Type 1, klart farveløst hætteglas med 20 mm chlorbutyl gummiprop og forseglet med grøn flipp-off aluminiumskapsel.
English: Please tell your doctor or hospital pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.
Danish: Fortæl det altid til lægen eller apotekspersonalet, hvis du tager anden medicin eller har gjort det for nylig.
English: All grades toxicity (%)
Danish: • Stabil sygdom (%)
English: Bullous conditions (blistering skin diseases)-including Stevens-Johnson syndrome and Toxic epidermal necrolysis
Danish: Bulløse tilstande (hudsygdomme med blæredannelser), inklusive Stevens-Johnsons syndrom og Toksisk epidermal nekrolyse.
English: When prepared as directed, reconstituted and infusion solutions of Pemetrexed Fresenius Kabi contain no antimicrobial preservatives.
Danish: Rekonstituerede opløsninger og infusionsopløsninger Ved forberedelse som angivet indeholder rekonstituerede opløsninger og infusionsopløsninger med Pemetrexed Fresenius Kabi ikke antimikrobielle konserveringsmidler.
English: Patients treated with pemetrexed and cisplatin required fewer transfusions (16.4% versus 28.9%, p<0.001), red blood cell transfusions (16.1% versus 27.3%, p<0.001) and platelet transfusions (1.8% versus 4.5%, p=0.002).
Danish: Patienter, der blev behandlet med pemetrexed og cisplatin, havde behov for færre transfusioner (16,4 % mod 28,9 %; p<0,001), transfusioner af røde blodlegemer (16,1 % mod 27,3 %; p<0,001) og blodpladetransfusioner (1,8 % mod 4,2 %; p=0,002).
English: Rarely seen events include Stevens-Johnson syndrome and Toxic epidermal necrolysis.
Danish: Sjældne bivirkninger omfatter Stevens-Johnson's syndrom og toksisk epidermal nekrolyse.
English: A multicentre, randomised, open label phase 3 study of pemetrexed versus docetaxel in patients with locally advanced or metastatic NSCLC after prior chemotherapy has shown median survival times of 8.3 months for patients treated with pemetrexed (Intent To Treat population n = 283) and 7.9 months for patients treated with docetaxel (ITT n = 288).
Danish: Et åbent, randomiseret fase 3-multicenterstudie med pemetrexed versus docetaxel til patienter med lokalt fremskreden eller metastatisk NSCLC (ikke-småcellet lungecancer), der tidligere var behandlet med kemoterapi, har vist en median-overlevelsestid på 8,3 måneder for patienter, som blev behandlet med pemetrexed (Intent To Treat (ITT)-population n = 283), og 7,9 måneder for patienter, som blev behandlet med docetaxel (ITT n = 288).
English: Progression free survival (PFS) and overall response rate were similar between treatment arms: median PFS was 4.8 months for pemetrexed plus cisplatin versus 5.1 months for gemcitabine plus cisplatin (adjusted hazard ratio 1.04; 95% CI = 0.94-1.15), and overall response rate was 30.6% (95% CI = 27.3-33.9) for pemetrexed plus cisplatin versus 28.2% (95% CI = 25.0-31.4) for gemcitabine plus cisplatin.
Danish: Progressionsfri overlevelse (PFS) og størrelsen af det totale respons var ens mellem de to behandlingsarme: Middel PFS var 4,8 måneder for pemetrexed plus cisplatin mod 5,1 måneder for gemcitabin plus cisplatin (justeret hazard ratio 1.04; 95 % CI = 0,94-1,15) og det totale respons var 30,6 % (95 % CI = 27,3- 33,9) for pemetrexed plus cisplatin mod 28,2 % (95 % CI = 25,0-31,4) for gemcitabin plus cisplatin.
English: Nadir platelets < 50,000/mm with bleeding a,
Danish: Nadir for trombocytter < 50.000/mm med blødning a, uanset ANC-nadir
English: Table 2 - Dose modification table for pemetrexed (as single agent or in combination) and cisplatin-Non-haematologic toxicities a, b
Danish: Tabel 2 - Dosisjustering for pemetrexed (som monoterapi eller i kombination) og cisplatinNon-hæmatologisk toksicitet a, b
English: Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.
Danish: Indenfor hver gruppe af bivirkninger med samme frekvens er bivirkningerne opstillet efter, hvor alvorlige bivirkningerne er.
English: Uncommon cases of acute renal failure have been reported with pemetrexed alone or in association with other chemotherapeutic agents (see section 4.4).
Danish: Ikke almindelige tilfælde af akut nyresvigt er rapporteret ved brug af pemetrexed alene eller i kombinationsbehandling med andre cytostatika (se pkt.
English: Pemetrexed + cisplatin
Danish: Pemetrexed + cisplatin Gemcitabine + cisplatin
English: NSCLC, second-line treatment
Danish: NSCLC, andetvalgsbehandling
English: Pemetrexed is incompatible with diluents containing calcium, including lactated Ringer's Injection and Ringer's Injection.
Danish: Pemetrexid er uforligelig med fortyndingsvæsker, der indeholder calcium, herunder lakteret Ringer's opløsning og Ringer's opløsning.
English: Pemetrexed is physically incompatible with diluents containing calcium, including lactated Ringer's injection and Ringer's injection.
Danish: Pemetrexed er fysisk inkompatibelt med fortyndingsmidler indeholdende calcium, herunder Ringers laktat og Ringers væske.
English: The use of calcium folinate / folinic acid in the management of pemetrexed overdose should be considered.
Danish: For at afhjælpe overdosering af pemetrexed bør det overvejes at anvende calciumfolinat/folsyre.
English: The table below provides the frequency and severity of undesirable effects considered possibly related to study drug that have been reported in > 5% of 839 patients with NSCLC who were randomized to receive cisplatin and pemetrexed and 830 patients with NSCLC who were randomized to receive cisplatin and gemcitabine.
Danish: Nedenstående tabel viser hyppigheden og sværhedsgraden af bivirkninger, der blev vurderet som muligt relateret til studiesubstans, og som blev rapporteret hos > 5 % af de 839 patienter med NSCLC, der blev randomiseret til at få cisplatin og pemetrexed, samt de 830 patienter med NSCLC, som blev randomiseret til at få cisplatin og gemcitabin.
English: Infectious and non-infectious disorders of the dermis, the hypodermis and/or the subcutaneous tissue have been reported with an unknown frequency (e.g. acute bacterial dermo-hypodermitis,
Danish: Infektiøse og ikke-infektiøse sygdomme i dermis, hypodermis og/eller det subkutane væv (f.eks. akut bakteriel dermo-hypodermitis, pseudocellulitis, dermatitis) er rapporteret med hyppigheden ikke kendt
English: NSCLC, first-line treatment
Danish: NSCLC, førstevalgsbehandling
English: Excipients: Mannitol, hydrochloric acid concentrated, trometamol
Danish: Hjælpestoffer: Mannitol, saltsyre koncentreret, trometamol.
English: The table below provides the frequency and severity of undesirable effects that have been reported in > 5 % of 168 patients with mesothelioma who were randomised to receive cisplatin and pemetrexed and 163 patients with mesothelioma randomised to receive single agent cisplatin.
Danish: Nedenstående tabel viser hyppigheden og sværhedsgraden af bivirkninger, der blev rapporteret hos > 5 % af 168 patienter med mesoteliom, som var randomiseret til behandling med cisplatin og pemetrexed, og 163 patienter med mesoteliom, som var randomiseret til monoterapi med cisplatin.
English: Pemetrexed is primarily eliminated unchanged by renal excretion.
Danish: Pemetrexed udskilles primært uforandret via nyrerne.
English: Pemetrexed was not mutagenic in either the in vitro chromosome aberration test in Chinese hamster ovary cells, or the Ames test. Pemetrexed has been shown to be clastogenic in the in vivo micronucleus test in the mouse.
Danish: Pemetrexed var hverken mutagent i in vitro-testen for kromosomafvigelse hos kinesiske hamstre eller i Ames-testen.
English: JMEN: Kaplan Meier plots of progression-free survival (PFS) and overall survival pemetrexed versus placebo in patients with NSCLC other than predominantly squamous cell histology:
Danish: JMEN: Kaplan Meier plot for progressionsfri overlevelse (PFS) og total overlevelse for pemetrexed versus placebo hos patienter med NSCLC, bortset fra cancer hovedsageligt bestående af pladeepitelceller
English: If pemetrexed solutions contact the mucous membranes, flush thoroughly with water.
Danish: Hvis pemetrexed-opløsning kommer i kontakt med slimhinderne, skal de skylles grundigt med vand.
English: Vitamin supplementation: your doctor will prescribe you oral folic acid (vitamin) or a multivitamin containing folic acid (350 to 1000 micrograms) that you must take once a day while you are taking Pemetrexed Fresenius Kabi.
Danish: Vitamintilskud: Du skal tage en folsyretablet eller en multivitamin indeholdende folsyre (3501000 mikrogram) 1 gang dagligt, mens du får Pemetrexed Fresenius Kabi.
English: Pemetrexed Fresenius Kabi is given in combination with cisplatin, another anti-cancer medicine, as treatment for malignant pleural mesothelioma, a form of cancer that affects the lining of the lung, to patients who have not received prior chemotherapy.
Danish: Pemetrexed Fresenius Kabi anvendes sammen med cisplatin, en anden medicin mod kræft, til behandling af malignt pleuramesoteliom, en kræftform som påvirker lungehinderne, til patienter, som ikke tidligere har fået kemoterapi.
English: A multicentre, randomised, open-label, Phase 3 study of pemetrexed plus cisplatin versus gemcitabine plus cisplatin in chemonaive patients with locally advanced or metastatic (Stage IIIb or IV) non-small cell lung cancer (NSCLC) showed that pemetrexed plus cisplatin (Intent-To-Treat [ITT] population n = 862) met its primary endpoint and showed similar clinical efficacy as gemcitabine plus cisplatin (ITT n = 863) in overall survival (adjusted hazard ratio 0.94; 95% CI = 0.84-1.05).
Danish: Et randomiseret, åbent, fase 3-multicenterstudie af pemetrexed plus cisplatin versus gemcitabin plus cisplatin med patienter, der ikke tidligere har fået kemoterapi, med lokalt fremskreden eller metastatisk (fase IIIb eller IV) ikke-småcellet lungecancer (NSCLC) viste, at pemetrexed plus cisplatin (Intent-To-Treat [ITT] population n=865) mødte dets primære endepunkt og viste lignende klinisk effekt som gemcitabin plus cisplatin (ITT n=863) på total overlevelse (justeret hazard ratio 0,94; 95 % CI = 0,84-1,05).
English: There is no relevant use of Pemetrexed Fresenius Kabi in the paediatric population in malignant pleural mesothelioma and non-small cell lung cancer.
Danish: Det er ikke relevant at bruge Pemetrexed Fresenius Kabi til malignt pleuramesoteliom og ikkesmåcellet lungecancer i den pædiatriske population.
English: An analysis of the impact of NSCLC histology on the treatment effect on overall survival was in favour of pemetrexed versus docetaxel for other than predominantly squamous histologies (n = 399, 9.3 versus 8.0 months, adjusted HR = 0.78; 95% CI = 0 .61-1.00, p = 0.047) and was in favour of docetaxel for squamous cell carcinoma histology (n = 172, 6.2 versus 7.4 months, adjusted HR = 1.56; 95% CI = 1.08-2.26, p = 0.018).
Danish: En analyse af virkningen på NSCLCs histologi for behandlingens virkning på overlevelse var til fordel for pemetrexed versus docetaxel bortset fra cancerformer hovedsageligt bestående af pladeepitelceller (n=399; 9,3 versus 8,0 måneder, justeret HR= 0,78; 95 % CI= 0,61-1,00; p= 0,047) og til fordel for docetaxel for karcinom af pladeepitelceller (n= 172; 6,2 versus 7,4 måneder, justeret HR = 1,56; 95 % CI= 1,08-2,26; p= 0,0018).
English: In clinical trials, cases of interstitial pneumonitis with respiratory insufficiency, sometimes fatal, have been reported uncommonly in patients treated with pemetrexed.
Danish: Tilfælde af pnemonia interstitialis med respiratorisk insufficiens, til tider dødeligt, er blevet rapporteret i ikke almindelig grad hos patienter behandlet med pemetrexed i kliniske studier.
English: In patients with normal renal function (creatinine clearance > 80 ml/min), high doses of non-steroidal anti-inflammatory medicinal product (NSAIDs, such as ibuprofen > 1600 mg/day) and acetylsalicylic acid at higher dose (> 1.3 g daily) may decrease pemetrexed elimination and, consequently, increase the occurrence of pemetrexed adverse events.
Danish: kan høje doser af nonsteroide anti-inflammatoriske lægemidler (NSAID-præparater såsom ibuprofen > 1600 mg/dag) og acetylsalicylsyre i høje doser (≥ 1,3 g daglig) nedsætte udskillelsen af pemetrexed, og dermed øge forekomsten af bivirkninger relateret til pemetrexed.
English: Clinically relevant CTC toxicities that were reported in < 1 % of the patients that were randomly assigned to pemetrexed include supraventricular arrhythmias.
Danish: De klinisk relevante CTC-toksiciteter, som blev rapporteret hos < 1 % af de patienter, der var randomiseret til pemetrexed, omfattede supraventrikulær arytmi.
English: This suggests that pemetrexed may impair male fertility.
Danish: Dette indikerer, at pemetrexed kan nedsætte fertiliteten hos hanner.
English: EMPHACIS, a multicentre, randomised, single-blind phase 3 study of pemetrexed plus cisplatin versus cisplatin in chemonaive patients with malignant pleural mesothelioma, has shown that patients treated with pemetrexed and cisplatin had a clinically meaningful 2.8-month median survival advantage over patients receiving cisplatin alone.
Danish: EMPHACIS, et randomiseret, enkeltblindet, fase 3-multicenterstudie med pemetrexed plus cisplatin versus cisplatin alene til patienter, der ikke tidligere havde fået kemoterapi, og som led af malignt pleuramesoteliom, viste, at de patienter, som blev behandlet med pemetrexed og cisplatin, havde en klinisk meningsfuld længere median-levetid på 2,8 måneder end patienter, som kun blev behandlet med cisplatin.
English: For infusion solution of pemetrexed, chemical and physical in-use stability was demonstrated for 21 days at refrigerated temperature and 7 days at room temperature.
Danish: Infusionsopløsninger af pemtrexed har vist sig at have en kemisk og fysisk i-brug stabilitet på 21 dage ved køleskabstemperatur og 7 dage ved stuetemperatur.
English: The active substance is pemetrexed.
Danish: - Aktivt stof: pemetrexed
English: Following pemetrexed plus cisplatin induction (4 cycles), treatment with pemetrexed was statistically superior to placebo for OS (median 13.9 months versus 11.0 months, hazard ratio = 0.78, 95%CI=0.64-0.96, p=0.0195).
Danish: Efter induktionsbehandling med pemetrexed plus cisplatin (4 serier) var behandling med pemetrexed statistisk bedre sammenlignet med placebo med hensyn til OS (median 13,9 måneder versus 11,0 måneder, hazard ratio = 0,78; 95 % CI=0,64-0,96; p=0,0195).
English: Therefore, the use of pemetrexed in patients with creatinine clearance of < 45 ml/min is not recommended (see section 4.2).
Danish: Pemetrexed anbefales derfor ikke til patienter med en kreatinin-clearance < 45 ml/min (se pkt.
English: In a study conducted in beagle dog by intravenous bolus injection for 9 months, testicular findings (degeneration/necrosis of the seminiferous epithelium) have been observed.
Danish: Der blev observeret påvirkning af testiklerne (degenerering/nekrose af seminifere epitel) i et studie udført i beaglehunde, der fik intravenøse bolusinjektioner i 9 måneder.
English: Due to the gastrointestinal toxicity of pemetrexed given in combination with cisplatin, severe dehydration has been observed.
Danish: Der er blevet observeret tilfælde af svær dehydrering, grundet den gastrointestinale toksicitet af pemetrexed i kombination med cisplatin.
English: Breastfeeding must be discontinued during Pemetrexed Fresenius Kabi treatment.
Danish: Amningen skal afbrydes under behandling med Pemetrexed Fresenius Kabi.
English: Median overall survival (months) (95% CI)
Danish: Median overlevelse (måneder) (95 % CI)
English: PARAMOUNT: Kaplan Meier plot of progression-free survival (PFS) and Overall Survival (OS) for continuation pemetrexed maintenance versus placebo in patients with NSCLC other than predominantly squamous cell histology (measured from randomisation)
Danish: PARAMOUNT: Kaplan Meier plot for progressionsfri overlevelse (PFS) og total overlevelse for pemetrexed vedligeholdelsesbehandling vs. placebo hos patienter NSCLC, bortset fra cancer hovedsageligt bestående af pladeepitelceller (målt fra randomisering)
English: Neutrophils decreased
Danish: Fald i neutrofiler
English: Due to the increased thrombotic risk in patients with cancer, the use of anticoagulation treatment is frequent.
Danish: Interaktioner, der er fælles for alle cytotoksiske stoffer På grund af den forøgede risiko for trombotiske komplikationer hos cancerpatienter, er antikoagulationsbehandling hyppigt anvendt.
English: Pemetrexed Fresenius Kabi 500 mg: Each vial contains 500 milligrams of pemetrexed (as pemetrexed diacid).
Danish: Pemetrexed Fresenius Kabi 500 mg: Hvert hætteglas indeholder 500 mg pemetrexed (som pemetrexeddiacid)
English: Very common( may affect more than 1 in 10 people) Low white blood cells
Danish: Bivirkninger med Pemetrexed Fresenius Kabi kan være: Meget almindelige (kan påvirke mere end 1 ud af 10 patienter) Lavt antal hvide blodlegemer
English: Pemetrexed Fresenius Kabi is also a treatment for patients with advanced stage of lung cancer whose disease has progressed after other initial chemotherapy has been used.
Danish: Pemetrexed Fresenius Kabi er også en behandling til patienter med fremskreden lungekræft, hvor sygdommen har udviklet sig, efter en anden indledende behandling med kemoterapi har været forsøgt.
English: The table below provides the frequency and severity of undesirable effects that have been reported in > 5 % of 265 patients randomly assigned to receive single agent pemetrexed with folic acid and vitamin B12 supplementation and 276 patients randomly assigned to receive single agent docetaxel.
Danish: Nedenstående tabel viser hyppigheden og sværhedsgraden af bivirkninger, der blev rapporteret hos > 5 % af 265 patienter, som var randomiseret til monoterapi med pemetrexed og tilskud af folsyre og B12vitamin, og 276 patienter, som var randomiseret til monoterapi med docetaxel.
English: For single use only.
Danish: Kun beregnet til engangsbrug.
English: If you have further questions, please ask your doctor or pharmacist.
Danish: Er du i tvivl, så spørg lægen eller apotekspersonalet.
English: The median time from the start of pemetrexed plus cisplatin induction therapy to the start of maintenance treatment was 2.96 months on both the pemetrexed arm and the placebo arm. Randomised patients received maintenance treatment until disease progression.
Danish: Median-tiden fra start af pemetrexed og cisplatin-induktionsbehandling til start af vedligeholdelsesbehandling var 2,96 måneder i både pemetrexed- og placeboarmen.
English: Check with your doctor or pharmacist if you are not sure.
Danish: Spørg lægen eller sundhedspersonalet, hvis der er noget, du er i tvivl om.
English: if you are breast-feeding; you must discontinue breast-feeding during treatment with Pemetrexed Fresenius Kabi.
Danish: hvis du ammer, skal du afbryde amningen under behandlingen med Pemetrexed Fresenius Kabi.
English: As a result, concomitant use of live attenuated vaccines is not recommended (see section 4.3 and 4.5).
Danish: Som et resultat heraf, frarådes samtidig indgift af levende svækkede vacciner (se pkt.
English: Clinically relevant CTC toxicity that was reported in < 1% of the patients that were randomly assigned to pemetrexed include: allergic reaction/hypersensitivity, erythema multiforme, supraventricular arrhythmia and pulmonary embolism.
Danish: Klinisk relevant CTC-toksicitet, som blev rapporteret hos < 1 % af de patienter, som var randomiseret til pemetrexed, omfatter: Allergisk reaktion/overfølsomhed, erythema multiforme, supraventrikulær arytmi og lungeemboli.
English: Common Neuropathy-sensory 7.4
Danish: Almindelig Sensorisk neuropati
English: Pemetrexed Fresenius Kabi is also given in combination with cisplatin for the initial treatment of patients with advanced stage of lung cancer.
Danish: Pemetrexed Fresenius Kabi er også en behandling, som gives sammen med cisplatin, som den indledende behandling af patienter med fremskreden lungekræft.
English: Neutrophils/ Granulocytes decreased
Danish: Fald i neutrophiler/ granulocytter Fald i leukocytter
English: Pemetrexed Fresenius Kabi 100 mg: Each vial contains 100 milligrams of pemetrexed (as pemetrexed diacid).
Danish: Pemetrexed Fresenius Kabi 100 mg: Hvert hætteglas indeholder 100 mg pemetrexed (som pemetrexeddiacid)
English: The median OS for the overall population (n = 663) was 13.4 months for the pemetrexed arm and 10.6 months for the placebo arm, hazard ratio = 0.79 (95% CI = 0.65-0.95, p
Danish: Den gennemsnitlige OS for den totale population (n = 663) var 13,4 måneder for pemetrexed-armen og 10,6 måneder for placebo-armen, hazard ratio = 0,79 (95 % CI = 0,65-0,95; p = 0,01192).
English: The study met its primary endpoint and showed a statistically significant improvement in PFS in the pemetrexed arm over the placebo arm (n = 472, independently reviewed population; median of 3.9 months and 2.6 months, respectively) (hazard ratio = 0.64, 95% CI = 0.51-0.81, p = 0.0002).
Danish: Studiets primære endepunkt blev mødt og viste en statistisk signifikant forbedring i PFS i pemetrexedarmen over for placebo-armen (n = 472, uafhængigt evalueret population; median på henholdsvis 3,9 måneder og 2,6 måneder) (hazard ratio = 0,64; 95 % CI = 0,51-0,81; p = 0,0002).